2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Treatment Considerations, Drug Development, Biological Therapies, Transfusion, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Pediatric, Pregnant
PAPER

2676 Alloantibody detection, delayed hemolytic transfusion reaction and hyperhemolysis during pregnancy in patients with sickle cell disease: A retrospective cohort study

Zuha Shabbir, MD, Lauren Arena, MD2, Veronica Ramirez, MD3, Fanny Poissant4, Costa M Kazadi, MS5, Alex Bourguignon, MD6, Benjamin Rioux-Massé, MD7, Nicolas Mercure-Corriveau, MD8, Anne-Sophie Lemay, MD9, Jules M. Ross, MD10, Stephanie Forte, MD, MSc11
1 University of Montreal, Montreal, Quebec, Canada
2 University of Montreal, Montreal, Quebec, Canada
3 University of Montreal, Montreal, Quebec, Canada
4 University of Montreal, Montreal, Quebec, Canada
5 CHUM University of Montreal Hospital Center, Montreal, Quebec, Canada
6 CHUM University of Montreal Hospital Center, Montreal, Quebec, Canada
7 CHUM University of Montreal Hospital Center, Montreal, Quebec, Canada
8 CHUM University of Montreal Hospital Center, Montreal, Quebec, Canada
9 CHUM University of Montreal Hospital Center, Montreal, Quebec, Canada
10 CHUM University of Montreal Hospital Center, Montreal, Quebec, Canada
11 CHUM University of Montreal Hospital Center, Montreal, Quebec, Canada
Introduction:?
Pregnancy in patients with sickle cell disease (SCD) is associated with substantial maternal and fetal morbidity. Although red blood cell (RBC) transfusion is a cornerstone of management, data regarding transfusion-related alloimmunization during pregnancy and its complications remain limited.
 

Objective:?
To characterize alloimmunization, acute or delayed hemolytic transfusion reactions (AHTR, DHTR), and hyperhemolysis (HHS) in transfused pregnant patients with SCD.
 

Methods:?
We conducted a retrospective study of pregnant patients with SCD who delivered between 2016 and 2025 at an academic institution and received at least one RBC transfusion from conception to 6 weeks post-partum. Medical records, laboratory data, and blood bank records were reviewed. Newly identified clinically significant alloantibodies (NIAs) were classified as probably or possibly attributable to transfusion using a province-wide transfusion database for complete transfusion history, historical and follow-up antibody screens, and adjudication by transfusion medicine specialists.
 

Results:
Of 134 pregnancies identified, 72 transfused pregnancies (TPs) in 52 patients met inclusion criteria (median 1 TP/patient, range 1-3). Median maternal age was 31 (range 21-44), with median gravidity of 2 (range 1-9). Pre-existing alloimmunization was present in 20% of TPs (n=15/72), representing 36% of TPs in chronic red cell exchange (RCE) patients (n=4/11) and 18% (n=11/61) of TPs in episodically transfused patients. Among
the 61 TPs occurring in patients who were not chronically transfused, 18% were in patients that had never been transfused (n=11/61), and 51% in patients transfused with less than 6 lifetime RBC units (n=31/61). 

In total, 1417 RBC units were transfused to pregnant SCD patients across 223 transfusion events (TEs). Six patients on pre-existing RCE programs represented 32% of TEs (n=71/223) and 45% of transfused units across 11 TPs.
 

Twenty-one alloantibodies were newly identified in 12 TPs (range 1-3), 16 (76%) of which were clinically significant, representing a clinically significant alloimmunization rate of 12.5% per TP (n=9/72). Among the 16 NIAs, 7 (44%) were found to be probably attributable to transfusion, 4 (25%) to be possibly attributable, and 5 (31%) unlikely to be attributable, corresponding to a transfusion-associated alloimmunization rate of 11% (n=8/72 TPs). Transfusion-associated NIAs included antibodies directed against antigens of the Rh (n=4), Kell (n=2), Kidd (n=2), Duffy (n=1), and MNS (n=2) groups.


Patients developing transfusion-associated NIAs received a median of 1 TE (range 1–5) and 6 RBC units (range 2–26) per TP. All transfusion-associated NIAs (n=11) occured in patients having received less than 20 lifetime RBC units, with 73% (n=8/11) having received 6 units or less. No significant associations were identified between NIA development and gravidity, previous alloimmunization, estimated lifetime transfusion burden, or number of transfusions during pregnancy.  

Guideline-adherent prophylactic antigen-matching protocol was followed in 99% (n=220/223) of TEs. No AHTRs occurred and 2 DHTRs were observed, both meeting criteria for HHS. All 3 TEs deviating from protocol resulted in alloimmunization, including an HHS requiring ICU admission.

Among infants born to mothers with alloimmunization or HHS, no cases of HDFN or neonatal anemia were identified. However, hemolytic work-up was only performed in 54% of infants (n=7/13). Two newborns required phototherapy despite negative hemolytic work-up.   

Conclusion:
?
Clinically significant alloimmunization occurred in 12.5% of transfused pregnant patients with SCD, with 69% of newly-identified antibodies being potentially attributable to transfusion. While no cases of HDFN were identified, maternal consequences of alloimmunization were significant, including limited compatible blood availability at time of delivery and HHS. Up to 64% of antibodies adjudicated as probably or possibly attributable to transfusion were potentially preventable with extended prophylactic antigen matching, although pregnancy itself is an alloimmunizing event and contribution of pregnancy-related sensitization cannot be fully excluded in this retrospective study.
These findings support further study of extended prophylactic antigen matching to reduce transfusion-attributable alloimmunization in pregnant patients with SCD.  
Zuha Shabbir, MD: No relevant conflicts of interest to declare.